These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

693 related items for PubMed ID: 33531429

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
    Fan S, Wang T, You F, Zhang T, Li Y, Ji C, Han Z, Sheng B, Zhai X, An G, Meng H, Yang L.
    Eur J Med Res; 2023 Mar 20; 28(1):129. PubMed ID: 36941687
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E, Mazagova M, Shao S, Wang X, Quirino H, Woods AK, Hampton EN, Rodgers DT, Kim CH, Schultz PG, Young TS.
    Int J Mol Sci; 2017 Oct 27; 18(11):. PubMed ID: 29077054
    [Abstract] [Full Text] [Related]

  • 7. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.
    Yeo SP, Kua L, Tan JW, Lim JK, Wong FH, Santos MD, Poh CM, Goh AX, Koh XY, Zhou X, Rajarethinam R, Chen Q, Her Z, Horak ID, Low L, Tan KW.
    Cancer Res Commun; 2024 Jun 04; 4(6):1410-1429. PubMed ID: 38717140
    [Abstract] [Full Text] [Related]

  • 8. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
    Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL.
    Clin Cancer Res; 2019 Apr 15; 25(8):2560-2574. PubMed ID: 30655315
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
    Jetani H, Navarro-Bailón A, Maucher M, Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial Saborido J, Kraus S, Mestermann K, Thomas S, Bonig H, Luu M, Monjezi R, Mougiakakos D, Sauer M, Einsele H, Hudecek M.
    Blood; 2021 Nov 11; 138(19):1830-1842. PubMed ID: 34289026
    [Abstract] [Full Text] [Related]

  • 14. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
    Zhang Q, Zhang Z, Liu G, Li D, Gu Z, Zhang L, Pan Y, Cui X, Wang L, Liu G, Tian X, Zhang Z.
    BMC Cancer; 2022 Nov 02; 22(1):1124. PubMed ID: 36320072
    [Abstract] [Full Text] [Related]

  • 15. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
    Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, Lulla P, Rouce RH, Cabral JMS, Ramos CA, Brenner MK, Mamonkin M.
    Mol Ther; 2019 Jan 02; 27(1):272-280. PubMed ID: 30391141
    [Abstract] [Full Text] [Related]

  • 16. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
    Wang T, Zhang K, You F, Ma R, Yang N, Tian S, An G, Yang L.
    Life Sci; 2023 Oct 15; 331():122024. PubMed ID: 37574043
    [Abstract] [Full Text] [Related]

  • 17. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model.
    Tachi T, Kijima N, Kuroda H, Ikeda S, Murakami K, Nakagawa T, Yaga M, Nakagawa K, Utsugi R, Hirayama R, Okita Y, Kagawa N, Kishima H, Imai C, Hosen N.
    Cancer Immunol Immunother; 2024 Oct 05; 73(12):256. PubMed ID: 39367952
    [Abstract] [Full Text] [Related]

  • 18. Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
    Wu G, Guo S, Luo Q, Wang X, Deng W, Ouyang G, Pu JJ, Lei W, Qian W.
    Front Immunol; 2023 Oct 05; 14():1093750. PubMed ID: 36845088
    [Abstract] [Full Text] [Related]

  • 19. Preclinical Evaluation of CRISPR-Edited CAR-NK-92 Cells for Off-the-Shelf Treatment of AML and B-ALL.
    Ureña-Bailén G, Dobrowolski JM, Hou Y, Dirlam A, Roig-Merino A, Schleicher S, Atar D, Seitz C, Feucht J, Antony JS, Mohammadian Gol T, Handgretinger R, Mezger M.
    Int J Mol Sci; 2022 Oct 24; 23(21):. PubMed ID: 36361619
    [Abstract] [Full Text] [Related]

  • 20. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H, Yang L, Chukinas JA, Shah N, Tarun S, Pouzolles M, Chien CD, Niswander LM, Welch AR, Taylor N, Tasian SK, Fry TJ.
    J Immunother Cancer; 2021 Sep 24; 9(9):. PubMed ID: 34531250
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.